Increase in Insulin Prices in the U.S. Leads to Federal Case Against Three Major Intermediary Companies

The Federal Trade Commission (FTC) of the United States has filed a lawsuit against three major pharmaceutical intermediaries, accusing them of steering diabetic patients towards higher-priced insulin in a "non-competitive" environment to receive millions of dollars in benefits from drug manufacturers. The lawsuit targets subsidiaries of "UnitedHealth Group," "CVS," and "Cigna," alleging that they unfairly remove lower-priced insulin products from insurance coverage lists. Reducing drug prices has been a key goal for the Biden administration, with Vice President Kamala Harris, a Democratic candidate in the upcoming presidential election, consistently emphasizing the need to work for patients' interests, particularly in lowering insulin prices. The three companies mentioned in the lawsuit account for 80% of all prescriptions in the U.S. They have described the lawsuit as "baseless" and defended their business practices, claiming they have reduced insulin prices for businesses, unions, and patients. Rahul Rao, an FTC official, referred to these companies as "gatekeepers of medicine," stating that they have extracted millions of dollars from the plight of patients who need life-saving medications. He noted, "Millions of Americans with diabetes need insulin to survive; however, for many of these vulnerable patients, drug costs have skyrocketed over the past decade due to the powerful intermediaries and their greed." The FTC, which aims to protect consumer rights, has not sued the three main insulin manufacturers—"Eli Lilly," "Sanofi," and "Novo Nordisk"—but has criticized their role in what it calls an "inefficient system," reserving the right to sue drug manufacturers later.